WO2009097014A3 - Therapeutic kinase modulators - Google Patents

Therapeutic kinase modulators Download PDF

Info

Publication number
WO2009097014A3
WO2009097014A3 PCT/US2008/074820 US2008074820W WO2009097014A3 WO 2009097014 A3 WO2009097014 A3 WO 2009097014A3 US 2008074820 W US2008074820 W US 2008074820W WO 2009097014 A3 WO2009097014 A3 WO 2009097014A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
kinase modulators
therapeutic kinase
relates
activity
Prior art date
Application number
PCT/US2008/074820
Other languages
French (fr)
Other versions
WO2009097014A2 (en
Inventor
Fabrice Pierre
Mustapha Haddach
Original Assignee
Cylene Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals, Inc. filed Critical Cylene Pharmaceuticals, Inc.
Priority to CA2698463A priority Critical patent/CA2698463A1/en
Publication of WO2009097014A2 publication Critical patent/WO2009097014A2/en
Publication of WO2009097014A3 publication Critical patent/WO2009097014A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
PCT/US2008/074820 2007-08-31 2008-08-29 Therapeutic kinase modulators WO2009097014A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2698463A CA2698463A1 (en) 2007-08-31 2008-08-29 Therapeutic kinase modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96955607P 2007-08-31 2007-08-31
US60/969,556 2007-08-31

Publications (2)

Publication Number Publication Date
WO2009097014A2 WO2009097014A2 (en) 2009-08-06
WO2009097014A3 true WO2009097014A3 (en) 2009-12-30

Family

ID=40523789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074820 WO2009097014A2 (en) 2007-08-31 2008-08-29 Therapeutic kinase modulators

Country Status (3)

Country Link
US (1) US7910600B2 (en)
CA (1) CA2698463A1 (en)
WO (1) WO2009097014A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135571A1 (en) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
CN102703456B (en) * 2012-05-15 2014-04-02 武汉生命之美科技有限公司 Action target site of death-associated protein kinase (DAPK3) gene hsa-miR-20a
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
CN107056819B (en) * 2017-04-17 2019-08-23 牡丹江医学院 A kind of drug and preparation method thereof preventing and treating myocardial ischemia
JP7277390B2 (en) * 2017-07-31 2023-05-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Anti-Cancer/Anti-Fibrosis Compounds
JP7335893B2 (en) 2017-12-22 2023-08-30 ラヴェンナ ファーマシューティカルズ，インコーポレイテッド Chromenopyridine Derivatives as Phosphatidylinositol Phosphate Kinase Inhibitors
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
TW202112784A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Chromenopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN114957252B (en) * 2022-07-14 2023-09-05 苏州施安鼎泰生物医药技术有限公司 Compound, preparation method thereof, pharmaceutical composition and application thereof in preparation of EED inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
US20030065180A1 (en) * 2000-03-28 2003-04-03 American Home Products Corporation Tricyclic protein kinase inhibitors
US20030069265A1 (en) * 2000-12-05 2003-04-10 Geeta Saxena Therapeutics for chemokine mediated diseases
WO2004007754A2 (en) * 2002-07-12 2004-01-22 Rigel Pharmaceuticals, Inc. Modulators of cellular proliferation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171985C (en) * 1976-02-10 1983-06-16 Rhone Poulenc Ind METHOD FOR PREPARING PREPARATIONS WITH ACTION AGAINST SCHISTOSOMIASIS, THE PREPARED PREPARATIONS SO GIVEN AND METHOD FOR PREPARING 1,2-DITHIOOL COMPOUNDS.
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6772081B1 (en) * 2002-05-21 2004-08-03 Data Recognition Corporation Priority system and method for processing standardized tests
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
NZ553746A (en) * 2004-09-17 2010-06-25 Cylene Pharmaceuticals Inc Quinolone analogs as cell proliferation inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
US20030065180A1 (en) * 2000-03-28 2003-04-03 American Home Products Corporation Tricyclic protein kinase inhibitors
US20030069265A1 (en) * 2000-12-05 2003-04-10 Geeta Saxena Therapeutics for chemokine mediated diseases
WO2004007754A2 (en) * 2002-07-12 2004-01-22 Rigel Pharmaceuticals, Inc. Modulators of cellular proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REWCASTLE ET AL.: "Synthesis of 4-(Phenylamino)pyrimidine Derivatives as ATP-Competitive Protein Kinase Inhibitors with Potential for Cancer Chemotherapy.", CURRENT ORGANIC CHEMISTRY, vol. 4, 2000, pages 679 - 706 *

Also Published As

Publication number Publication date
US7910600B2 (en) 2011-03-22
US20090093465A1 (en) 2009-04-09
WO2009097014A2 (en) 2009-08-06
CA2698463A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
MX2009002298A (en) Serine-threonine protein kinase and parp modulators.
WO2009097014A3 (en) Therapeutic kinase modulators
IN2012DN02596A (en)
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
WO2005020921A3 (en) C-kit modulators and methods of use
WO2010006086A3 (en) Kinase inhibitors and methods of use
MY159483A (en) Variants of activin iib receptor polypeptides and uses thereof
WO2010006072A3 (en) Mtor modulators and uses thereof
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MY158447A (en) Compounds modulating c-fms and/or c-kit activity and uses thereof
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
BRPI0813311A2 (en) COMPOUND, METHODS FOR MODULATING THE ACTIVITY OF A PROTEIN KINASE AND FOR TREATING CANCER IN AN INDIVIDUAL AND PHARMACEUTICAL COMPOSITION.
WO2006033943A3 (en) Pyrazole kinase modulators and methods of use
EA017150B9 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2009035818A8 (en) Compounds that modulate intracellular calcium
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
WO2007062243A3 (en) Serum-free expansion of cells in culture
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2007008982A3 (en) Methods and composition for modulating foxo1 activity and insulin signaling
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
DE602006018461D1 (en) GALK1S AS PTEN / ACT WAY MODIFICATORS
WO2013118128A3 (en) Cellular apobec3 proteins and modulators thereof for reglulating dna repair processes and treating proliferative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08871845

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2698463

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08871845

Country of ref document: EP

Kind code of ref document: A2